Souhaitez-vous accéder aux communiqués récents ?

NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The passing of Rev. Jesse L. Jackson, Sr. has cast a spotlight on progressive supranuclear palsy (PSP), one of the most misunderstood neurodegenerative...

Operating capital runway sufficient into the fourth quarter of 2026 In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8 data submitted in late...

RetinalGenix signs agreement to hire M. Cory Zwerling as its chief financial officer and interim chief operating officer, effective January 1, 2026

Gnome Sciences Discovers Cancer Drug Shows Promise in Stopping Progression of ALS. BCL2 inhibitors such as venetoclax may treat neurodegenerative diseases

First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine Aggregated TDP-43 is a pathological hallmark of...

Boston, Oct. 16, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Anti-Parkinson's Drugs: Global Markets to 2030” is projected to grow from $6.1 billion in 2025 to $9.2...

Groundbreaking study demonstrates that targeted oligodendrocyte gene therapy leads to decreased N-acetylaspartate (NAA) levels and increased brain myelin.

RetinalGenix Technologies and RGEN Announce Strategic Collaboration to Advance Early Detection of Neurodegenerative, Systemic, and Retinal Diseases.

Therini Bio announced the dosing of the first patient in their Phase 1b trial evaluating THN391 in Alzheimer's Disease

Therini Bio raised a $39M Series A financing, bringing the Series A total to $75M, from top-tier investors to commence THN391 Ph 1b AD and DME studies